<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114916</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-0005</org_study_id>
    <nct_id>NCT04114916</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Reduction of Cardiovascular Risk</brief_title>
  <acronym>NUT</acronym>
  <official_title>Clinical Trial to Evaluate the Efficacy of a Nutraceutical Versus Placebo in Reducing Cardiovascular Risk in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized parallel and double blind clinical trial in which it is intended to analyze the
      efficacy of a nutraceutical on cholesterol and endothelial function after the consumption of
      a product for eight weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>The measurements of endothelial function are taken with an ultrasound on two different occasions. The measurements will be made at baseline and after eight weeks of product consumption.</time_frame>
    <description>Changes in the dilatation of the Humeral artery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood samples</measure>
    <time_frame>Total cholesterol measurements are taken with the ILAB 600 analyzer on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product.</time_frame>
    <description>Change in total cholesterol levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tests</measure>
    <time_frame>Quality of life measurements are taken on two different occasions. Measurements are made at the beginning and after eight weeks of product consumption.</time_frame>
    <description>Change in physical activity with the World Physical Activity Questionnaire (GPAQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nutritional record</measure>
    <time_frame>The dietary intake will be controlled by a diary in which meals will be recorded for three days and on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product.</time_frame>
    <description>Volunteers record dietary intake for three days in a notebook. They will describe the amount of food they consume in grams in order to assess changes in intake during the clinical trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body composition</measure>
    <time_frame>Body measurements are taken with a Tanita on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product.</time_frame>
    <description>Changes in body composition were measured with a TANITA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular risk</measure>
    <time_frame>Cardiovascular risk measurements are taken by laboratory analysis on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product.</time_frame>
    <description>Changes in systolic blood pressure (mmHg), dystolic blood pressure (mmHg) and heart rate (beats per minute).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tests</measure>
    <time_frame>Quality of life measurements are taken on two different occasions. Measurements are made at the beginning and after eight weeks of product consumption.</time_frame>
    <description>Change in the quality of life (SF-12).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cholesterol</condition>
  <arm_group>
    <arm_group_label>Apigenin, luteonin, grapefruit extract and citrolive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsules a day. It will be consumed at breakfast for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrina</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsules a day. It will be consumed at breakfast for eight weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Apigenin, luteonin, grapefruit extract and citrolive</intervention_name>
    <description>Two capsules daily at breakfast and dinner.</description>
    <arm_group_label>Apigenin, luteonin, grapefruit extract and citrolive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrina</intervention_name>
    <description>Two capsules daily at breakfast and dinner.</description>
    <arm_group_label>maltodextrina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of both sexes (men or women) between 40 and 75 years of age, of Caucasian
             race

          -  Women must be in the menopausal period.

          -  Present body mass index between 18.5 and 34.9 Kg / m2.

          -  The number of platelets in whole blood must be greater than 170 x109 / L

          -  Hematocrit greater than 40% for men or greater than 35% for women.

          -  Hemoglobin greater than 120 g / L for men or 110 g / L for women.

          -  Present fasting levels of LDL-serum cholesterol equal to or greater than 110mg / dL

          -  Present fasting values of total serum cholesterol equal or superior to 180mg / dL

          -  Volunteers able to understand the clinical study and willing to give written informed
             consent and to comply with the procedures and requirements of the study.

        Exclusion Criteria:

          -  Thyroid dysfunction, infections, or with any type of chronic disease (for example,
             autoimmune, inflammatory).

          -  Subjects who have suffered an ischemic-vascular event during the last months

          -  Subjects undergoing medication and / or nutraceutical treatment for hypertension,
             diabetes or hyperlipidemia (eg Statins).

          -  Subjects under treatment with drugs that due to their narrow therapeutic margin
             require monitoring of their plasma levels (digoxin, acenocoumarol, warfarin, etc ...)

          -  Subjects under treatment that affect body weight or appetite.

          -  History of allergic hypersensitivity or poor tolerance to any component of the
             products under study.

          -  Subjects who are performing or intend to perform any type of diet, hypocaloric or not,
             during the conduct of the study.

          -  Subjects who have donated a minimum of 0.5L of blood in the last month.

          -  Vegetarian subjects.

          -  Subjects, who have ingested, in the last three months, supplements of omega 3 and / or
             6, (eg fish oil, evening primrose oil, krill oil, or algae oil).

          -  Subjects under treatment with niacin or fibrates.

          -  Those subjects with alcohol abuse, or with excessive alcohol consumption (&gt; 3 glasses
             of wine or beer / day) will be excluded.

          -  Patients undergoing major surgery in the last 3 months.

          -  Subjects who smoke or not, but in any case who do not modify their nicotinic habits
             during their participation in the study.

          -  Participation in another clinical trial in the three months prior to the study Lack of
             will or inability to comply with clinical trial procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

